ESSENTIAL THROMBOCYTHEMIA
Overview
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.
Do you Qualify?
These questions require a yes answer to qualify.
-
Are you at least 18 years of age?
-
Are resistant to or intolerant of Hydroxyurea, that is, fulfilling at least 1 of the following criteria:
-
Platelet count > 600× 109/L after 3 months of at least 2 g/day of HU (2.5 g/day in subjects with a body weight over 80 kg) OR at the subject's maximally tolerated dose if that dose is < 2 g/day.
-
Platelet count > 400 × 109/L and WBC count < 2.5 × 109/L or hemoglobin (Hgb) < 10 g/dl at any dose of HU.
-
Presence of leg ulcers or other unacceptable muco-cutaneous manifestations at any dose of HU.
-
HU-related fever.
-
Platelet count > 650 × 109/L at screening
-
WBC > 11.0 × 109/L at screening.
These questions require a no answer to qualify.
-
Are you currently pregnant, plan to become pregnant or breastfeeding?
-
Are you currently suffering from any heart diseases or low liver function?
-
Are you currently suffering from any major illnesses that may require extended hospitalization?
-
Are you currently suffering from an active alcohol or drug addiction?
If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.